Continuing Education and Professional Development

The University of Tennessee Graduate School of Medicine Department of Anesthesiology presents the 2024 Targeted Pain Treatment® Conference on March 22, 2024, at the Hilton Knoxville Airport. This year's conference theme will focus on providing hope for patients with pain.

Course Overview

Health providers are aware of the challenges with the opioid crisis across east Tennessee, as are our patients. As opioids are no longer recommended as first line therapy for the management of chronic pain, clinicians are at a loss for what options are out there for those patients whose quality of life is limited by their pain. Our goal is to provide clinicians and patients with hope that there is a way to effectively treat their pain and improve their function without relying solely on opioids.

We are going to present the scientific basis of hope in terms of hope theory and how targeted pain treatment is linked to the scientific basis of hope. Targeted pain treatment, the process of accurately diagnosing the cause of pain, and then targeting the treatment to the cause, is an effective comprehensive approach to addressing the cause of pain and improving function and quality of life for patients. By relating targeted pain treatment to the scientific basis of hope, we aim to assist providers in promoting hopefulness in their patients who currently feel limited by their pain.

Targeted Pain Treatment® the process of accurately diagnosing the cause of pain, and then targeting the treatment to the cause, is an alternate, effective, and comprehensive approach to addressing the cause of pain and improving function and quality of life for patients.

This conference is officially endorsed by the Tennessee Pain Society.

Requirements for continuing medical education credit regarding controlled substance prescribing

Targeted Pain Treatment® is a federally registered trademark owned by Dr. Stephanie Vanterpool. Dr. Vanterpool developed and is responsible for the content contained in the TPT Toolkit.

Course Directors

Stephanie G. Vanterpool MD, MBA, FASA
Director, Comprehensive Pain Services
Assistant Professor, Department of Anesthesiology
University of Tennessee Graduate School of Medicine
Immediate Past President - Tennessee Pain Society
Director at Large - North American Neuromodulation Society (NANS)
Co-Chair-Diversity and Outreach Committee, NANS

Hannah Denham, PharmD, BCPS
Clinical Pharmacist Specialist
University Health Network - University Center for Pain Management of Knoxville

Che A. Solla, MD, MBA
Assistant Professor, Department of Anesthesiology
University of Tennessee Graduate School of Medicine

Course Objectives

At the conclusion of this program, the participants should be able to:

Discuss the scientific basis of hope and how scientific theory relates to targeted pain treatment
Identify ways to apply the state and national guidelines that govern opioid prescribing and chronic pain treatment
Discuss specific treatment options to address challenging pain presentations

Registration Fees Fees include access to online program materials, continuing education credit hours, breakfast, lunch, breaks, and parking at the Hilton Knoxville Airport.
	Early Bird	February 19, 2024
Physician	$200	$250
Non-Physician	$150	$200
Resident and Students (no CME credit)	$25	$50

Accreditation

The University of Tennessee College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Education Credits

The University of Tennessee College of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants, Nurse Practitioners and Nurses may use these credit hours toward certification renewal. This credit is acceptable by the American Academy of Physician Assistants (AAPA), American Nurses Credentialing Association (ANCC) and the American Academy of Nurse Practitioners (AANP).

Disclosures

There is no minimum threshold for financial disclosures; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies within the past 24 months. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

The UT Graduate School of Medicine Office of Continuing Education and Professional Development along with the Co-Course Directors have taken appropriate steps to mitigate relationships prior to the individuals assuming their roles. CME Planning Staff have no actual or potential conflicts of interest in relation to the presentations.